Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxych loroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients
Comparison of HC
Q, nitazoxanide, and ivermectin showing similar effectiveness for overall clinical outcomes in COVID-19 when used before seven days of symptoms, and overwhelmingly superior compared to the untreated COVID-19 population, even for those outcomes not influenced by placebo effect, at least when combined with azithromycin, and vitamin C, D and zinc in the majority of the cases.
585 patients with mean treatment delay 2.9 days. There was no hospitalization, mechanical ventilation, or mortality.
death, ↓82.8%, p=0.21, control group 1
ventilation, ↓95.5%, p=0.0008, control group 1
hospitalization, ↓98.4%, p<0.0001, control group 1
(adjusted for zero)